Organon Past Earnings Performance
Past criteria checks 4/6
Organon's earnings have been declining at an average annual rate of -34.7%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 0.4% per year. Organon's return on equity is 694.4%, and it has net margins of 15.8%.
Key information
-34.7%
Earnings growth rate
-34.9%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -0.4% |
Return on equity | 694.4% |
Net Margin | 15.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Sep 19These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
Sep 13Organon & Co.: Cheap With Caveats
Aug 22Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Aug 09Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price
Aug 07Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Jul 30Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)
Nov 05Organon: Thoughts Ahead Of Q3 Earnings
Oct 31Organon: What Is The Recipe?
Aug 31Oragenics announces early toxicology data for intranasal COVID-19 vaccine
Aug 24Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
Aug 17Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Aug 07Revenue & Expenses Breakdown
How Organon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 6,346 | 1,000 | 1,873 | 499 |
31 Mar 24 | 6,347 | 1,047 | 1,887 | 511 |
31 Dec 23 | 6,263 | 1,023 | 1,891 | 528 |
30 Sep 23 | 6,150 | 585 | 1,892 | 536 |
30 Jun 23 | 6,168 | 754 | 1,794 | 526 |
31 Mar 23 | 6,145 | 746 | 1,766 | 504 |
31 Dec 22 | 6,174 | 917 | 1,702 | 471 |
30 Sep 22 | 6,292 | 1,011 | 1,717 | 439 |
30 Jun 22 | 6,355 | 1,107 | 1,665 | 398 |
31 Mar 22 | 6,365 | 1,304 | 1,658 | 368 |
31 Dec 21 | 6,304 | 1,351 | 1,669 | 339 |
30 Sep 21 | 6,314 | 1,525 | 1,620 | 289 |
30 Jun 21 | 6,327 | 1,762 | 1,553 | 257 |
31 Mar 21 | 6,258 | 1,917 | 1,421 | 232 |
31 Dec 20 | 6,532 | 2,256 | 1,356 | 210 |
31 Dec 19 | 7,777 | 3,306 | 1,443 | 220 |
31 Dec 18 | 9,777 | 2,153 | 1,956 | 365 |
31 Dec 17 | 10,500 | 1,801 | 2,250 | 355 |
Quality Earnings: OGN has high quality earnings.
Growing Profit Margin: OGN's current net profit margins (15.8%) are higher than last year (12.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OGN's earnings have declined by 34.7% per year over the past 5 years.
Accelerating Growth: OGN's earnings growth over the past year (32.6%) exceeds its 5-year average (-34.7% per year).
Earnings vs Industry: OGN earnings growth over the past year (32.6%) exceeded the Pharmaceuticals industry 13%.
Return on Equity
High ROE: Whilst OGN's Return on Equity (694.44%) is outstanding, this metric is skewed due to their high level of debt.